Lumen Biosciences
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Biopharmaceuticals, Synthetic biology
- Founded
- 2017 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Lumen Bioscience Inc Seattle business license
- Stage
- Startup
- Founders
- Brian Finrow, Jim Roberts
Seattle Biotech Lumen Bioscience Raises $30M Series C Extension, Adds Microsoft Vet Jeff Raikes to Board
Seattle biotech startup Lumen Bioscience raised a $30 million Series C extension led by WestRiver Group, bringing total funding to $186.8 million to advance its oral biologic drugs. The company also added Microsoft veteran Jeff Raikes to its board and announced several leadership updates.
Lumen Bioscience adds Jeff Raikes to board, promotes executives and secures $30M Series C extension led by WestRiver Group
Lumen Bioscience announced board and leadership changes—including Jeff Raikes joining as an independent director, promotions of Nhi Khuong and Kole Krieger, and appointment of David Saunders—and elected Erik Anderson as Vice Chairman. The company also closed an oversubscribed $30 million Series C extension led by WestRiver Group with participation from the Gates Foundation and several new investors to support its orally delivered biologics clinical pipeline.
A-Alpha Bio raises $20M Series A led by Madrona to expand Seattle lab and scale protein-discovery platform
University of Washington spinout A-Alpha Bio raised $20 million in Series A funding led by Madrona Venture Group to expand downtown Seattle lab space and grow its machine-learning team for its protein-discovery platform. The company combines computational tools and yeast-based experiments to generate large protein-interaction datasets used to predict therapeutic protein candidates for diseases including COVID-19.
Lumen Bioscience and Google use machine learning to double spirulina protein yields; research backed by $2M DOE grant
Seattle biotech Lumen Bioscience and Google collaborated on machine-learning research that doubled spirulina-based protein production, supported by a $2 million DOE grant and backing from the Gates Foundation.
Sana Biotechnology to build 163,000 sq ft Fremont biomanufacturing facility to produce T cell therapies, stem cells and viral DNA
Sana Biotechnology will build a 163,000 sq. ft. biomanufacturing facility in Fremont, California to produce T cell therapies, human stem cells, and viral DNA, expanding its operations beyond Seattle after a $587 million IPO. The three-year-old gene-editing and cell therapy company plans to use the site for late-stage clinical and early commercial manufacturing and is hiring across Seattle, San Francisco, and Boston.
Lumen Bioscience to convert former Wallingford bakery into algae plant, quintupling spirulina output after $16M Series B
Seattle biotech Lumen Bioscience will convert a former Wallingford bakery into an algae-based manufacturing facility to roughly quintuple spirulina production from about 3 kg per week, following a $16M Series B and several new partnerships and grants.
Lumen Bioscience raises $16M Series B to scale Spirulina platform for orally delivered antibodies; total funding $68M
Lumen Bioscience raised $16 million in a Series B to advance its Spirulina-based platform that produces orally delivered antibodies and biologics for GI diseases, claiming dramatically lower costs and three clinical programs. The Seattle startup, co‑founded in 2017 by CEO Brian Finrow and CSO Jim Roberts, has partnerships with the Gates Foundation, NIH and others and has raised $68 million to date.
Gates Foundation Awards $800,000 to A-Alpha Bio to Fund AlphaSeq Antibody Research Targeting SARS-CoV-2 and Intestinal Pathogens
Seattle biotech A-Alpha Bio received an $800,000 grant from the Bill & Melinda Gates Foundation to support research using its AlphaSeq platform to develop multi-target antibody treatments for respiratory viruses, including SARS-CoV-2, and intestinal pathogens such as campylobacter, in partnership with Lumen Bioscience.
A-Alpha Bio wins $620,472 NSF Phase II SBIR to develop molecular-glue discovery system
Seattle startup A-Alpha Bio received a $620,472 NSF Phase II SBIR grant to develop a system that identifies molecular glues which tag disease-causing proteins for cellular degradation, aiming to target previously 'undruggable' proteins for diseases like Alzheimer’s, cancer and autoimmune disorders.
People
-
Jeff Raikes Board Member
